Skip to main content
TipRanks
Go Ultimate75% OFF

Filana Therapeutics (PX91) Q3 2024 Earnings Report

8 Followers

DE:PX91 Q3 2024 EPS Results

Actual EPS
-EUR 0.52
Consensus EPS
-EUR 0.66
Beat/Miss
Beat by +EUR 0.14
One Year Ago EPS
-EUR 0.55

DE:PX91 Q3 2024 Revenue Results

Actual Revenue
EUR 0
Expected Revenue
EUR 0
Beat/Miss
Met expectations
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q3 2024
Date
11/07/2024
Time
Before Open
Conference Call
Thursday, November 7, 2024
DE:PX91 Upcoming Earnings

Filana Therapeutics's next earnings date is estimated for March 2, 2027, based on past reporting schedules.

Q3 2024 Earnings Call Audio

DE:PX91 Q3 2024 Earnings Call
0:00 / 0:00

Q3 2024 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2024 Earnings Call Summary

Q3 2024
Earnings Call Date:Nov 07, 2024|% Change Since:-97.76%|
Earnings Call Sentiment|Neutral

The earnings call presented a mix of promising progress in clinical trials and financial stability, but also highlighted increased administrative costs and legal challenges. The anticipation of Phase III trial results is a critical point of focus.

Company Guidance

During Cassava Sciences' Q3 2024 earnings call, CEO Richard Barry provided guidance on the company's upcoming milestones and financial outlook. He emphasized the anticipated release of top-line results from the Phase III RETHINK-ALZ trial before the end of the year, highlighting the potential for a best-in-class treatment for Alzheimer's disease. The company plans to report biomarker data for approximately 100 patients, focusing on plasma markers such as pTau 217, Neurofilament Light Chain (NFL), Glial Fibrillary Acidic Protein (GFAP), and total tau. Financially, Cassava Sciences ended the quarter with $149 million in cash, which is expected to be sufficient for operations through the conclusion of ongoing Phase III trials and into 2026. Net cash used in operations for the first nine months of 2024 was $55.7 million, with projections for the second half ranging between $80 million and $90 million, inclusive of a $40 million SEC settlement. The company's net loss for Q3 was $27.9 million, with R&D expenses decreasing as more patients transition to a lower-cost open-label study.

  • Phase III Trial ProgressAnnounced the last patient visit for the Phase III trial RETHINK-ALZ, with top-line results expected by the end of the year.
  • Cash Position and Financial StabilityEnded Q3 with $149 million in cash, expected to fund operations through the conclusion of ongoing Phase III trials and into 2026.
  • Reduced R&D ExpensesR&D expenses for Q3 were $17.7 million, down from $23.6 million in the same period last year as more patients transition from Phase III to lower-cost open-label studies.
  • Biomarker InnovationDiscussed the potential of plasma biomarker tests with high correlation to Alzheimer's diagnosis, which could transform treatment by primary care physicians.

DE:PX91 Earnings History

DE:PX91 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 02, 20272026 (Q4)-0.23--0.24――
Nov 05, 20262026 (Q3)-0.22-0.20-0.20.00% (+0.00)
Aug 05, 20262026 (Q2)-0.20-0.16-0.8380.43% (+0.67)
May 07, 20262026 (Q1)-0.21-0.19-0.4356.25% (+0.24)
Mar 12, 20262025 (Q4)-0.27-0.24-0.5254.39% (+0.28)
Nov 12, 20252025 (Q3)-0.24-0.20-0.5262.07% (+0.33)
Aug 14, 20252025 (Q2)―-0.830.12-807.69% (-0.95)
May 08, 20252025 (Q1)―-0.43-0.39-11.63% (-0.05)
Mar 03, 20252024 (Q4)-0.53-0.52-0.45-14.00% (-0.06)
Nov 07, 20242024 (Q3)-0.66-0.52-0.554.92% (+0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed